Received by email:

File: '\\office\emailin\20220421 032343 Attachment Press Release CBD Patent, April 2022 .docx'










Pascal Biosciences First To File Patent 
For COVID-19 Antiviral Activity With CBD 

VANCOUVER, BRITISH COLUMBIA, April 21, 2022- Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS) (OTC:PSCBF
--->) (FSE: 6PB-FF) was the first to report cannabinoids can kill SARS-CoV-2, the virus that causes Covid-19. Pascal filed
---> an international patent covering this work prior to the press release in July 2020, and now it is clear that Pascal w
--->as the first to file to protect this discovery. This means that Pascal holds the rights to therapeutic treatment of Co
--->vid-19 by cannabinoids, particularly CBD. Pascal scientists have replicated this work in four different antiviral assa
--->ys and have also shown that CBD has an antiviral activity similar to remdesivir, a Gilead Sciences drug approved for t
--->reatment of Covid-19.  Furthermore, Pascal's discovery has been confirmed and extended by several academic groups. A l
--->ab at the University of Chicago has recently shown that CBD suppressed infection in mice, and also that epilepsy patie
--->nts treated with CBD have significantly lower rates of SARS-CoV-2 infection than matched patients. A separate academic
---> study suggests that CBD viral blockade is not variant specific, so CBD treatment should be beneficial as the virus mu
--->tates during the pandemic.

There are currently at least four clinical trials testing CBD in Covid-19 patients. While Pascal is not involved in th
--->ose studies, the rights to treat patients would be covered by Pascal's patent if CBD is approved by regulatory officia
--->ls. After 18 months, patent submissions become public information. The absence of other patents predating Pascal's sub
--->mission date confirm that Pascal was the first to file and protect this discovery.

"It is rewarding to see external studies independently confirming CBD as having a positive impact with respect to Covi
--->d-19", stated Brian Bapty, Pascal BioSciences CEO. "CBD is a well characterized drug, and the real world patient data 
--->is looking constructive for its use against Covid-19. This suggests clinical studies designed to support FDA approval 
--->will be well informed as to expected outcome."


ABOUT PASCAL BIOSCIENCES INC.

Pascal is a biotechnology company targeting innovative therapies for cancer, including targeted therapies for acute ly
--->mphoblastic leukemia and cannabinoid-based therapeutics. Pascal's leading portfolio also comprises a small molecule th
--->erapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-s
--->timulatory cannabinoid to be used in combination with checkpoint inhibitor therapy.

To learn more, visit: https://www.pascalbiosciences.com/. 

On Behalf of the Board of Directors
Dr. Brian Bapty, CEO 
Company Contact:
Dr. Patrick Gray
Email: pgray@pascalbiosciences.com
Investors:
invest@pascalbiosciences.com
Tel: 206-221-3443

Forward-Looking Statements 
DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securiti
--->es Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that 
--->may not be based on historical fact, including without limitation statements containing the words "believe", "may", "p
--->lan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking s
--->tatements or information involve known and unknown risks, uncertainties and other factors that may cause our actual re
--->sults, events or developments, or industry results, to be materially different from any future results, events or deve
--->lopments express or implied by such forward-looking statements or information. Such factors include, among others, our
---> stage of development, lack of any product revenues, additional capital requirements, risk associated with the complet
--->ion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectu
--->al property, dependence on collaborative partners and the prospects for negotiating additional corporate collaboration
--->s or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actu
--->al events or results expressed or implied by such forward-looking statements and information to differ materially from
---> any future events or results expressed or implied by such statements and information include, but are not limited to,
---> the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or futu
--->re products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; 
--->we may not be able to raise additional capital; we may not be successful in establishing additional corporate collabor
--->ations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products ma
--->y be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to
---> intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and oth
--->er factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com.
---> Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements
---> and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements a
--->nd information made herein are based on our current expectations and we undertake no obligation to revise or update su
--->ch forward- looking statements and information to reflect subsequent events or circumstances, except as required by la
--->w.

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the
---> TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"